Mr Melki has led the commercialisation efforts of Genetic Signatures as Chief Executive Officer since 2011. Dr. Melki originally joined Genetic Signatures in 2003 where he was responsible for leading the commercialisation of two research products worldwide and five diagnostic products locally and Europe in the role of Senior Principal Research Scientist. He has authored over 20 peer-reviewed articles and is listed as an inventor on eight patent applications. His primary research focus was in the sodium bisulphite conversion of DNA which is at the core of Genetic Signatures'3base technology.
